期刊
BRITISH JOURNAL OF CANCER
卷 114, 期 1, 页码 14-20出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/bjc.2015.434
关键词
triple-negative breast cancer; androgen receptor; pathological complete response; luminal androgen receptor; intrinsic subtype
类别
资金
- Ministry of Education, Science, Sports, Culture and Technology of Japan [25461992, 26461957]
- Grants-in-Aid for Scientific Research [26461957, 25461992] Funding Source: KAKEN
Background: Triple-negative breast cancer (TNBC) patients testing positive for androgen receptor (AR) expression are thought to be chemotherapy resistant, similar to other hormone receptor-positive breast cancers; however, this has not been substantially validated in the clinic. In this study, we investigated the association between chemotherapy sensitivity and AR expression in patients treated with neoadjuvant chemotherapy (NAC) using standardised chemotherapy criteria and regimens. Methods: A total of 177 patients with resectable early-stage breast cancer were treated with NAC. Oestrogen receptor, progesterone receptor, HER2, Ki67 and AR status were assessed immunohistochemically. Results: Sixty-one patients were diagnosed with TNBC; AR expression was identified in 23 (37.7%), which was significantly less common than that found in non-TNBC patients (103 of 116; 88.8%; P<0.001). The rate of pathological complete response after NAC was significantly lower (P - 0.001), and disease recurrence was more common (P - 0.008) in patients with AR-positive compared with those with AR-negative TNBC. In TNBC cases, as expected, the non-recurrence period in cases that were negative for AR expression was significantly extended (P - 0.006, log-rank). Conclusions: Androgen receptor expressions may be useful as biomarkers to predict treatment responses to NAC in TNBC. Moreover, induction of a change in subtype to the AR-negative phenotype was observed after NAC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据